Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease

On Thursday, Merck & Co Inc MRK reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion.Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., due to lower demand in China, partially offset by higher sales in the U.S., driven by public-sector buying patterns, higher pricing and demand, and higher demand in most international regions.Beyond ...